Investors
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 1, 2024
Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing NEW YORK, Oct. 1, 2024 /PRNewswire/ --...
-
Sep 24, 2024
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...
-
Sep 10, 2024
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...
-
Sep 3, 2024
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid...
-
Aug 20, 2024
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...